自体干细胞移植对比强化化疗巩固治疗急性髓系白血病患者的长期获益:来自PETHEMA AML登记处的倾向性评分匹配分析
基于PETHEMA AML登记处的真实世界回顾性队列研究,纳入1272例首次缓解且接受2个巩固疗程的AML患者,比较自体干细胞移植与化疗巩固。总体队列中auto-SCT与显著延长的OS(HR 0.73)和RFS(HR 0.73)相关,但倾向性评分匹配后RFS优势持续(HR 0.80,p=0.092)而OS差异无统计学意义(HR 0.91,p=0.563)。
要点
- 总体队列中auto-SCT与显著延长的OS(HR 0.73)和RFS(HR 0.73)相关。
- 倾向性评分匹配后RFS优势持续(HR 0.80,p=0.092),OS差异无统计学意义(HR 0.91,p=0.563)。
- 获益在≤65岁、正常核型及FLT3-ITD阴性患者中尤为明显。
核心结论
- 在无法或不宜进行allo-SCT时,auto-SCT对比化疗巩固在总体队列中与显著延长的OS和RFS相关,但倾向性评分匹配后OS差异无统计学意义。
- auto-SCT在基因组学和靶向药物时代的作用不应被丢弃。
研究设计与样本
- 真实世界回顾性队列研究,使用PETHEMA AML登记处数据。
- 采用多因素Cox回归和倾向性评分匹配调整混杂因素。
- 共纳入1272例首次缓解且接受2个巩固疗程的患者,615例接受额外化疗周期,657例接受auto-SCT。
主要发现
- 总体中78.08%的auto-SCT患者诊断于2017年前,化疗队列为38.11%(p < 0.001)。
- 总体队列中auto-SCT与显著延长的OS相关(HR: 0.73,p < 0.001)。
- 总体队列中auto-SCT与显著延长的RFS相关(HR: 0.73,p < 0.001)。
- 获益在≤65岁、正常核型及FLT3-ITD阴性患者中尤为明显。
- 倾向性评分匹配队列中RFS优势持续(HR: 0.80,p = 0.092),OS差异无统计学意义(HR: 0.91,p = 0.563)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While allogeneic stem cell transplantation (allo-SCT) is the preferred consolidation for high and most intermediate-risk acute myeloid leukemia (AML) patients in first remission, the role of autologous SCT (auto-SCT) vs. chemotherapy (CT) when allo-SCT is not feasible or indicated, remains controversial. We conducted a real-world, retrospective cohort study using the PETHEMA AML registry to compare auto-SCT and CT. Multivariate Cox regression and propensity score matching (PS-matching) were used to adjust for confounding factors. A total of 1272 patients in first remission and who received 2 consolidation courses were included (615 receiving additional CT cycles and 657 undergoing auto-SCT). Overall, 78.08% of auto-SCT patients were diagnosed before 2017, compared to 38.11% in the CT cohort (p < 0.001). In the overall cohort, auto-SCT was associated with significantly prolonged overall survival (OS) (HR: 0.73, p < 0.001) and relapse-free survival (RFS) (HR: 0.73, p < 0.001). This benefit was particularly evident in patients ≤65 years, those with normal karyotype, and FLT3-ITD negativity. In the PS-matched cohort, the RFS advantage persisted (HR: 0.80, p = 0.092), but OS differences were not statistically significant (HR: 0.91, p = 0.563). The role of auto-SCT in the genomic and targeted agent era should not be discarded.
引用
- Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, et al. Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry. Leukemia. 2025. PMID: 40890512. doi:10.1038/s41375-025-02744-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。